Last 47 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -62.32 | — | — | — | — | 19.70 | — | 33.48 | 11.30 | 18.58 | 4263.75 | 339.67 | — | — | 31.23 | 20.74 | 282.08 | 51.64 | 18.79 | 182.25 | 16.67 |
| — | — | — | — | — | +6.0% | — | -90.1% | — | — | +13551.5% | +1537.9% | — | — | +66.2% | -88.6% | +1592.3% | +188.5% | -68.4% | +1551.6% | +136.8% | |
| P/S Ratio | 3.42 | 3.08 | 3.59 | 3.37 | 3.52 | 2.70 | 3.05 | 2.93 | 2.49 | 2.21 | 3.30 | 2.42 | 2.45 | 3.02 | 3.68 | 3.31 | 2.63 | 2.61 | 3.25 | 2.50 | 2.44 |
| — | +14.3% | +17.5% | +14.9% | +41.5% | +21.9% | -7.6% | +20.9% | +1.6% | -26.7% | -10.2% | -26.7% | -6.9% | +15.7% | +13.1% | +32.4% | +7.6% | -12.4% | +20.1% | +6.1% | +35.1% | |
| P/B Ratio | 2.25 | 2.62 | 2.77 | 2.68 | 2.57 | 1.68 | 1.78 | 1.97 | 1.73 | 1.56 | 2.04 | 1.73 | 1.65 | 1.78 | 2.48 | 2.50 | 2.18 | 2.11 | 2.40 | 1.95 | 1.79 |
| — | +56.1% | +55.9% | +36.2% | +48.5% | +7.8% | -13.1% | +14.0% | +5.1% | -12.6% | -17.7% | -30.8% | -24.4% | -15.6% | +3.5% | +28.2% | +22.2% | -1.6% | +27.4% | +7.4% | +13.1% | |
| P/FCF | 53.48 | — | 11.20 | 36.66 | — | 7.69 | 15.11 | 11.55 | 8.19 | 10.48 | 12.43 | 8.85 | 10.54 | — | 11.58 | 19.48 | 34.01 | 6.19 | 143.77 | 8.16 | — |
| — | — | -25.9% | +217.4% | — | -26.7% | +21.5% | +30.5% | -22.3% | — | +7.4% | -54.5% | -69.0% | — | -91.9% | +138.7% | — | -32.0% | +1306.1% | -23.5% | — | |
| EV / EBITDA | 43.37 | — | 37.91 | 17.78 | — | 12.48 | 43.10 | 12.46 | 7.19 | 8.54 | 26.66 | 18.86 | 12.11 | 131.92 | 26.47 | 11.63 | 27.10 | 15.55 | 24.81 | 24.11 | 10.51 |
| — | — | -12.1% | +42.7% | — | +46.2% | +61.7% | -33.9% | -40.6% | -93.5% | +0.7% | +62.2% | -55.3% | +748.1% | +6.7% | -51.8% | +157.8% | +35.3% | +24.4% | +216.6% | +102.3% | |
| EV / EBIT | — | — | — | 417.05 | — | 25.08 | — | 19.02 | 9.75 | 20.29 | — | 393.90 | 36.73 | — | 64.85 | 17.47 | 428.84 | 38.97 | 34.73 | 56.78 | 11.84 |
| — | — | — | +2093.2% | — | +23.6% | — | -95.2% | -73.5% | — | — | +2155.3% | -91.4% | — | +86.7% | -69.2% | +3522.8% | +205.3% | +49.7% | +603.7% | +109.4% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.6% | 84.6% | 88.7% | 89.1% | 90.1% | 89.8% | 89.5% | 85.0% | 90.0% | 89.4% | 88.6% | 88.1% | 87.3% | 84.4% | 84.7% | 86.3% | 85.4% | 88.0% | 88.2% | 89.3% | 87.8% |
| — | -5.8% | -0.8% | +4.8% | +0.2% | +0.5% | +0.9% | -3.5% | +3.1% | +5.8% | +4.6% | +2.1% | +2.2% | -4.0% | -4.0% | -3.4% | -2.7% | +6.9% | -0.4% | +2.6% | +1.9% | |
| Operating Margin | -5.1% | -26.5% | -3.6% | 6.5% | -31.4% | 7.3% | -6.8% | 12.3% | 23.2% | 13.4% | -2.2% | -0.6% | 5.3% | -13.0% | 3.4% | 20.5% | -0.9% | 6.7% | 1.3% | 3.8% | 22.0% |
| — | -460.6% | +47.7% | -46.8% | -234.9% | -45.3% | -211.9% | +2127.5% | +339.6% | +203.4% | -165.2% | -103.0% | +715.9% | -294.4% | +161.0% | +435.2% | -103.9% | -72.4% | -87.2% | -87.2% | -39.3% | |
| Net Margin | -5.4% | -26.6% | -1.1% | -1.9% | -23.5% | 13.6% | -7.9% | 8.8% | 21.9% | 11.8% | 0.1% | 0.7% | -10.4% | -0.6% | 11.0% | 15.2% | 1.0% | 4.6% | 16.8% | 1.5% | 14.5% |
| — | -296.0% | +86.0% | -122.0% | -207.2% | +14.9% | -9247.0% | +1130.8% | +311.1% | +2030.2% | -99.2% | -95.3% | -1152.7% | -113.3% | -34.4% | +891.8% | -93.2% | -72.4% | +286.2% | -92.8% | -43.7% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -3.7% | -5.5% | -0.2% | -0.4% | -4.3% | 2.1% | -1.1% | 1.5% | 3.9% | 2.1% | 0.0% | 0.1% | -1.7% | -0.1% | 1.9% | 2.9% | 0.2% | 0.9% | 3.1% | 0.3% | 2.7% |
| — | -357.8% | +81.3% | -125.9% | -208.9% | +1.8% | -8642.5% | +1070.5% | +324.7% | +2427.8% | -99.3% | -95.6% | -944.6% | -109.6% | -39.5% | +875.9% | -92.4% | -69.4% | +310.2% | -92.9% | -53.6% | |
| ROA | -2.7% | -4.0% | -0.2% | -0.3% | -3.2% | 1.6% | -0.9% | 1.1% | 2.9% | 1.5% | 0.0% | 0.1% | -1.2% | -0.1% | 1.0% | 1.5% | 0.1% | 0.5% | 1.5% | 0.2% | 1.4% |
| — | -341.8% | +82.2% | -125.3% | -211.2% | +8.4% | -9174.0% | +1133.3% | +333.7% | +2920.8% | -99.0% | -93.9% | -1300.9% | -111.4% | -37.0% | +897.2% | -92.5% | -69.4% | +307.1% | -92.6% | -48.3% | |
| ROIC | -2.8% | -4.8% | -0.6% | 1.1% | -4.8% | 1.0% | -0.8% | 1.6% | 3.1% | 1.8% | -0.3% | -0.1% | 0.7% | -1.1% | 0.3% | 2.1% | -0.1% | 0.7% | 0.1% | 0.4% | 2.5% |
| — | -596.8% | +25.9% | -32.1% | -252.7% | -47.5% | -199.8% | +1964.3% | +360.4% | +260.4% | -188.8% | -104.0% | +783.4% | -252.1% | +121.1% | +376.9% | -104.0% | -72.3% | -87.9% | -87.6% | -47.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | 0.58 | 0.50 | 0.52 | 0.53 | 0.54 | 0.52 | 0.52 |
| — | +30.4% | +21.2% | +16.6% | +6.2% | -28.5% | -30.9% | -26.6% | -18.3% | -9.0% | -92.1% | -91.0% | -91.1% | -91.3% | +6.8% | -4.1% | +1.0% | +0.7% | -2.6% | -5.9% | -11.6% | |
| Debt / EBITDA | 0.75 | — | 2.19 | 1.06 | — | 0.95 | 3.19 | 0.85 | 0.63 | 0.92 | 2.39 | 2.01 | 1.41 | 13.45 | 20.37 | 8.06 | 21.93 | 13.53 | 19.14 | 22.71 | 10.64 |
| — | — | -31.4% | +23.9% | — | +2.7% | +33.2% | -57.6% | -55.6% | -93.1% | -88.2% | -75.1% | -93.6% | -0.6% | +6.4% | -64.5% | +106.1% | +33.6% | -9.2% | +165.9% | +64.6% | |
| Current Ratio | 1.90 | 2.08 | 1.96 | 1.90 | 1.80 | 2.58 | 2.44 | 2.35 | 2.20 | 1.91 | 1.73 | 1.70 | 1.56 | 1.68 | 1.21 | 1.07 | 0.91 | 0.85 | 2.00 | 1.91 | 2.85 |
| — | -19.3% | -19.8% | -18.8% | -18.2% | +34.8% | +41.0% | +38.1% | +40.5% | +14.2% | +43.3% | +59.2% | +70.9% | +97.3% | -39.6% | -44.1% | -67.9% | -62.3% | -17.9% | -25.8% | +54.6% | |
| Quick Ratio | 1.66 | 1.84 | 1.72 | 1.66 | 1.56 | 2.43 | 2.26 | 2.16 | 1.98 | 1.69 | 1.49 | 1.43 | 1.27 | 1.32 | 1.08 | 0.93 | 0.80 | 0.73 | 1.69 | 1.63 | 2.59 |
| — | -24.1% | -23.9% | -23.1% | -21.3% | +43.2% | +51.8% | +50.8% | +55.3% | +28.5% | +37.8% | +53.4% | +59.1% | +79.5% | -35.8% | -42.9% | -69.1% | -64.2% | -24.2% | -31.2% | +52.4% | |
| Interest Coverage | — | -23.90 | — | — | — | — | — | — | — | — | — | — | — | -17.82 | 6.99 | 23.05 | 0.74 | 7.26 | 8.58 | 1.35 | 5.89 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SUPN stock.
Supernus Pharmaceuticals, Inc.'s current P/E is -62.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Supernus Pharmaceuticals, Inc.'s current operating margin is -5.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Supernus Pharmaceuticals, Inc.'s business trajectory between earnings reports.